Entity
Description
  • Value proposition

    A leading CRO in drug discovery and preclinical services

    Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services.
    Founded in 1995, Oncodesign Services mission’ is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing,

    Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.).

    Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities.

    As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates.

    Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program.

    Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m2 of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.


    Kinase inhibitor Drug & Biomarker Discovery, Novel inflammatory target based drug discovery, Oncology advanced in vitro and in vivo pharmacology, Immunomodulation in oncology, DMPK/ADME, Medicinal chemistry, Bioanalysis, Translational Biomarkers, Biobanking, Biodecontamination/Biosafety, medicinal chemistry, drug discovery, drug analysis, Biopharma, Partnering, inflammatory diseases, infectious diseases, vitro assay development, and vivo models

  • Original language

    CRO spécialisée en drug discovery et services précliniques

    Oncodesign Services est société de recherche contractuelle (CRO) spécialisée dans la découverte de médicaments et les services précliniques.

    Fondée en 1995, Oncodesign Services a pour mission de contribuer à la découverte de thérapies innovantes, dans les domaines de l'oncologie, de l'inflammation et des maladies infectieuses. De l'identification de cible jusqu'au dépôt d'IND, Oncodesign Services accompagne les programmes R&D de clients internationaux (laboratoires pharmaceutiques, biotechs, instituts de recherche).
    Oncodesign Services propose une gamme complète de services de drug discovery tels que la chimie médicinale, la DMPK, la pharmaco-imagerie, la bioanalyse, les tests in vivo/in vitro et les modèles de tumeurs. Nos capacités couvrent les petites molécules, les théranostiques et les nouvelles entités biologiques, soit par des projets autonomes (SOLO), ou par des programmes intégrés (DRIVE).

    Pionnier en médecine translationnelle, le défi de l'entreprise repose sur une accélération des cadences pour un développement plus rapide – du laboratoire au patient – mais aussi sur l’élaboration d’une proposition thérapeutique différenciée et innovante. Pour cela, Oncodesign Services utilise de nouvelles voies technologiques pour identifier et sélectionner les meilleurs candidats médicaments.

    Oncodesign Services dispose de laboratoires BSL1, BSL2 et BSL3 et tous les sites maintiennent l'accréditation internationale AAALAC de notre programme de soin et d'utilisation des animaux.

    Basé à Dijon, au sein du pôle Paris-Saclay et à Montréal, Oncodesign Services bénéficie de 2000m2 de laboratoires de chimie et biologie à la pointe de la technologie. Oncodesign Services compte 230 collaborateurs en France, au Canada et aux Etats-Unis, avec de hautes compétences en drug discovery et pharmacologie translationnelle.

  • Oncodesign Services - CRO in Drug discovery

    Oncodesign Services is a CRO specializing in drug discovery & preclinical services, in oncology, inflammation and infectious diseases.

  • https://www.oncodesign-services.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Eurazeo
Eurazeo
Finance, Financial Services
Eurazeo
Finance, Financial Services
Other

22 Jan 2024


Dijon métropole
Dijon métropole
Government Administration, French metropolis
Dijon métropole
Government Administration, French metropolis
Not capitalistic
Partnership
Event

21 May 2021


Région Bourgogne-Franche-Comté
Région Bourgogne-Franche-Comté
National and local authorities, Government Administration
Région Bourgogne-Franche-Comté
National and local authorities, Government Administration
Other

16 Mar 2024


SOCFIM
SOCFIM
Bank, Banking
SOCFIM
Bank, Banking
Other

21 Sep 2018


Servier Pharmaceuticals
Servier Pharmaceuticals
Pharmaceutical, Pharmaceutical Manufacturing
Servier Pharmaceuticals
Pharmaceutical, Pharmaceutical Manufacturing
Not capitalistic
Partnership
Not event

25 Dec 2022


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
Not capitalistic
Partnership
Event

18 Mar 2024


Medicen Paris Region
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Other

11 Mar 2024


CEA
CEA
Research
CEA
Research
Other

26 Nov 2021


Lyonbiopôle Auvergne-Rhône-Alpes
Lyonbiopôle Auvergne-Rhône-Alpes
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Lyonbiopôle Auvergne-Rhône-Alpes
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Not capitalistic
Not partnership
Event

22 Jan 2021


Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC
Government Administration
Not capitalistic
Not partnership
Event

25 May 2023


Similar entities
Loading...
Loading...
Social network dynamics